Physician profile
William J Will
NPI 1568471860
$7,290.74
in general payments reported to CMS, 2019-2025
42 companies · $1,476 in 2025
The $1,476 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $426 · 2020: $491 · 2021: $731 · 2022: $1,182 · 2023: $1,535 · 2024: $1,448 · 2025: $1,476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,453 · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,453.37 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $747.62 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $696.05 | 2021-2025 | Vraylar, Viberzi, Linzess |
| Lilly USA, LLC | $677.09 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $664.23 | 2020-2025 | Jardiance |
| Novo Nordisk INC | $659.33 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $590.44 | 2021-2025 | |
| Pfizer INC. | $574.41 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $389.01 | 2019-2025 | Xifaxan |
| Exact Sciences Corporation | $241.63 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Currax Pharmaceuticals LLC | $194.90 | 2021-2025 | Contrave, Onzetra Xsail, Nexlizet |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $160.94 | 2024-2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $155.95 | 2022-2023 | |
| Allergan, INC. | $154.56 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $141.46 | 2021-2024 | Xarelto, Spravato |
| Glaxosmithkline, LLC. | $100.96 | 2022-2024 | Shingrix, Arexvy |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Will listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.